Financially, UroGen has a market cap of $464mn and a cash runway of 8-9 quarters, despite facing patent challenges from Teva.

In an increasingly interconnected world, global health faces constant threats from new and re-emerging pathogens. Recent devastating outbreaks of diseases ...